|
GENOUS™ SUCCESS STORY
The story of a 24-year-old man walking again with osteosarcoma (SE)
THE CHALLENGE
With conventional treatments exhausted and his condition worsening, the outlook was grim. His medical team knew they needed a new approach—one that could target the cancer at its roots.
A 24-year-old man faced a tough battle with Ewing sarcoma, a rare and aggressive form of bone cancer. Despite undergoing multiple rounds of chemotherapy and immunotherapy, his disease continued to progress, leaving him confined to a wheelchair.
PRECISION CANCER SOLUTIONS
Turning to the latest in precision oncology, the Oncompass team performed a tissue biopsy-based NGS-406, to uncover the genetic secrets of his cancer. Genomate® analyzed his genetic data, and proposed a list of potential treatment options. The molecular tumor board carefully reviewed the Genomate Report and recommended a combination of Olaparib and Pazopanib. This combination was selected based on the specific molecular characteristics of the patient’s tumor
THE RIGHT DRUG. THE FIRST TIME. EVERYTIME
The patient responded immediately to the treatment, regaining his ability to walk. It was a victory not just over cancer, but over the limitations it had imposed on the patient’s life.
For the treatment team, this means:
-
Higher success rate
-
Make decisions faster
-
Limit guesswork and side effects
-
Give patients the best treatment opportunities
OUTCOMES AND IMPACT OF TARGETED THERAPY